Using OEE Monitoring to Justify Expenditure on Aging Production Lines

Pharmaceutical companies are accelerating upgrades across their manufacturing operations to achieve the interconnected standards of Pharma 4.0. The projected industry demand highlights the need for more efficiency, where the market valuation is expected to nearly double from $665 billion to $1059 billion between 2026 and 2034.^1,2

However, rising operational expenses, volatile supply lines, and increasing capacity constraints³ now compel drug manufacturers to rethink how they operate to achieve business targets. Many facilities can no longer absorb global disruptions without threatening critical output and eroding bottom-line margins.

Consequently, pharmaceutical organizations running aging machinery are moving capital expenditure (capex) directly into next-generation production lines. Using Industry 4.0 as a benchmark, leaders are replacing isolated workstations with data-driven systems for deeper insights, scalability, and adaptability to an expanding number of manufacturing bottlenecks.

In these modern upgrades, continuous overall equipment effectiveness (OEE) tracking is one of the most practical starting points for implementing Pharma 4.0. Pinpointing hidden downtime and process bottlenecks in real time gives leadership the visibility needed to maximize productivity.

Understanding Aging Pharma Production Lines

The term aging production line does not refer only to older assets failing to meet ever-growing pharmaceutical manufacturing demands. It also describes an operational strategy to adapt to the current industry climate. Legacy equipment and workflows based on staff instincts leave facilities unable to keep pace with dynamic market pressures and shifting business objectives.

But business pressures are not the only concern for industry leaders. Regulators are also raising expectations around data integrity and process control. In early 2026, Quality System Management Regulation (QSMR) came into effect, a regulatory decision that removed exemptions of protected internal quality audits from FDA inspections.⁴

These regulations mean that providing manufacturing-ready device data has become a compliance essential for any potential inspection. Meeting these changing standards requires continuous quality oversight, not periodic reviews.

Without the ability to adapt to regulatory changes such as these, production workflows can create compliance gaps. The most prominent example is FDA inspections, where an inability to provide device quality data can disrupt operations.

Manufacturers simply cannot afford interruptions caused by compliance or operational issues. The rapid advancements in gene and cell therapy and biologics are examples how manufacturers now require a more scalable, resilient production line to meet rising patient demand.⁵

Factory supervisors and managers cannot wait for equipment to fail before repairing it if they want to increase quantity and quality output. Unplanned downtime directly disrupts supply chains and can significantly spike costs.

Pharmaceutical leaders must now direct capital toward intelligent, data-driven technologies aligned with Industry 4.0 principles. Data-driven software, in particular, can be a key asset in helping manufacturers adapt aging production lines to meet current demand without major investment.

Building the Capex Case for OEE Monitoring

OEE scores can be key to justifying capital allocation cases. Integrating software that provides real-time performance metrics can provide deeper, more accurate insights into current operating capacity.

Rather than relying on rough estimates or traditional gut feelings in manufacturing, modern OEE software captures performance metrics that target the industry’s 4 primary manufacturing pain points. It provides the empirical foundation required to move from reactive to planned maintenance, support compliance reporting, unlock more production capacity, and track energy use.

OEE monitoring, which tracks availability, performance, and quality, can help identify and address common manufacturing losses such as microstops, speed loss, and yield variations in real time. Implementing a method that enables continuous visibility lets plant directors resolve bottlenecks faster and more effectively.

Ultimately, it can help turn underperforming pharma production lines into high-performing assets without requiring substantial equipment replacement.⁶ This visibility can help demonstrate measurable return on investment (ROI) as leaders decide which assets need attention when modernizing aging production lines.

The following sections break down the specific business case for each pain point, detailing how targeted OEE investments can pay for themselves on the factory floor. In practice, that means showing leadership which assets to replace, which to retrofit, and which to leave as-is.

Pushing a Strategic Production Shift

OEE monitoring can enable a strategic shift toward the predictive culture⁷ needed to keep pharma production lines scalable and adaptable to evolving business objectives. Relying on reactive maintenance can inflate operational expenditures through ruined batches, emergency repairs, and unplanned downtime. Live OEE monitoring captures activity logs that can detect microstops and speed loss early, enabling teams to fix emerging issues before they trigger potentially challenging line failures.

OEE platforms show how much output an aging asset is losing, and when, in a simple dashboard. Continuous visibility replaces guesswork with a steady stream of hard performance data. Decision makers can more accurately understand how much aging production lines weigh on the manufacturer’s budget.

Access to these data provides the evidence to identify when temporary fixes become more expensive than procuring advanced machinery. When the recurring costs of patching legacy equipment outweigh the price of modern replacement, OEE data, combined with maintenance cost records, provide a stronger business case.

A real-world example of a successful strategic shift comes from Megalabs, whose primary challenge was improving visibility and efficiency. OEE improved by over 47% in 9 months, enabling data-driven decision-making and streamlining operations into 1 unified space to help address problems before they became costly.⁸

Reducing Regulatory Compliance Risks

Many governments, especially those with a significant pharma manufacturing industry, continue to tighten regulatory frameworks. Sustainability has been a keyword at a World Health Organization (WHO) summit, where many regulatory bodies, including the Europe Medicines Agency (EMA) and the Africa Medicines Agency (AMA), pledged to build a roadmap to further remove the environmental footprint of pharmaceutical products.⁹

Any of these sudden legislative changes or advice of regulators could also mean production lines may need to adapt quickly to new operating rules. Compliance failures could result in considerable penalties for the organization.

Adaptive capabilities will be key in rapidly changing regulatory climates. OEE platforms can support compliance by providing quality metrics for continuous operational oversight, identifying potential risks, and enabling faster corrective action.

Integrating more detailed quality tracking can help allocate capex to form a more effective risk-mitigation strategy. With consistent quality data across lines, leadership can show where upgrades would reduce deviations and yield losses, which strengthens the investment case.

Unlocking Capacity Through Targeted Capex

Though regulatory compliance is essential to operations, unlocking capacity is arguably one of the most important considerations when justifying capex. OEE tracking can help identify whether an underperforming line is experiencing availability bottlenecks due to aging assets.

When performance data show that core machinery is still performing well, decision makers can bypass expensive full-line replacements in favor of targeted retrofits. Digital monitoring software can help facilities unlock hidden capacity for a fraction of full-replacement capital.

A targeted approach stretches capital expenditure further, recovering lost throughput and delivering faster return on investment without the costly downtime of equipment overhauls.

Addressing Sustainability with Utility Tracking

Finally, sustainability is also part of the capex case. Ensuring production lines are energy efficient not only supports regulatory compliance and internal environmental, social, and governance (ESG) goals, but also significantly reduces operating costs.¹⁰

Modern OEE software can help in achieving sustainability objectives by tracking utility usage. Live metrics, directly alongside line availability and speed, can show how much energy the line machinery consumes during unexpected downtime. By correlating energy spikes with equipment inefficiencies, these platforms build a case for investing in more modern, energy-efficient systems.

Tracking energy performance gives leadership the data needed to meet ESG targets while lowering utility spend. Turning sustainability from a theoretical pledge into verifiable production line data helps direct capital toward upgrades that cut both energy costs and emissions.

OEE Monitoring: Data-Driven Justification

Relying on gut instinct or traditional retrospective feedback is no longer viable in an evolving pharmaceutical manufacturing climate. Decision makers demand detailed financial justification before signing off on major investments into modern assets, especially when managing aging manufacturing infrastructure.

Digital OEE monitoring provides the proof required to build justifiable capex proposals for legacy pharma production lines. By converting machine metrics into quantifiable losses across availability, performance, and quality, leadership can identify where investment will yield fast, measurable returns.

Having such operational visibility can bridge the divide between daily plant operations and corporate strategy. Production teams can make targeted investments that reduce long-standing line bottlenecks. At the same time, executive suites receive the metrics needed to hit margin, compliance, and sustainability commitments.

Moving toward Pharma 4.0 with tools such as OEE monitoring equips facilities with the adaptability and scalability to meet the demands of an increasingly volatile pharmaceutical market.

References

1. Damodharan M, Gabhale A. Using automation to enhance manufacturing: building the foundation for Pharma 4.0. PharmTech. October 13, 2026. Accessed October 29, 2026. https://www.pharmtech.com/view/using-automation-to-enhance-manufacturing-building-the-foundation-for-pharma-4-0
2. Fortune Business Insights. Pharmaceutical manufacturing market size, share & industry analysis, by route of administration, by molecule type, by drug development, by sales channel, by therapy area, by prescription, by age group, by formulation, and regional forecast, 2026-2034. Pune: Fortune Business Insights; October 12, 2026. Report No.: FBI116596. Accessed October 30, 2026.https://www.fortunebusinessinsights.com/pharmaceutical-manufacturing-market-116596
3. Carder J. What are the biggest challenges pharmaceutical manufacturers are facing today? MarketScale. August 3, 2026, updated September 1, 2026. Accessed October 29, 2026. https://www.marketscale.com/industries/engineering-and-construction/what-are-the-biggest-challenges-pharmaceutical-manufacturers-are-facing-today
4. Overview of device regulation. FDA. January 30, 2026. Accessed October 30, 2026.https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/overview-device-regulation
5. Molloy-Brookes D. The great rebuild: why pharmaceutical manufacturing is being restructured from the ground up. Life Sciences Week. June 24, 2026. Accessed October 29, 2026.https://lifesciencesweek.co.uk/the-great-rebuild-why-pharmaceutical-manufacturing-is-being-restructured-from-the-ground-up/
6. Evocon. Pharmaceutical manufacturing monitoring. Tallinn: Evocon. Accessed October 29, 2026. https://evocon.com/pharmaceuticals/
7. Bataille J. 2026 trends and risk insights for a new era of innovation in pharma manufacturing. World Insurance Associates. December 3, 2025. Accessed October 29, 2026.https://www.worldinsurance.com/blog/2026-pharma-manufacturing-trends-and-risk-insights
8. Akk A. Megalabs' journey to Industry 4.0. Evocon. June 27, 2024. Updated September 3, 2024. Accessed October 30, 2026.https://evocon.com/articles/case_study/megalabs-journey-to-industry-4-0/
9. WHO and global regulators advance shared roadmap for greener pharmaceuticals. World Health Organization. July 10, 2026 Accessed October 30, 2026.https://www.who.int/news/item/10-07-2026-who-and-global-regulators-advance-shared-roadmap-for-greener-pharmaceuticals
10. Cole C. Industry outlook 2026: navigating AI, sustainability, and operational resilience. PharmTech. January 13, 2026;50(1):8–10. Accessed October 29, 2026.https://www.pharmtech.com/view/industry-outlook-2026-navigating-ai-sustainability-and-operational-resilience

About the Author

Breandán Flood is a content developer at Evocon, which makes OEE and production monitoring software for manufacturers. He writes about overall equipment effectiveness (OEE), production efficiency and shop-floor performance. He has also written case studies on how manufacturers in the beverage, building materials, and paper and packaging sectors have used production data to find losses and improve output.